Autosomal Dominant Polycystic Kidney Disease News and Research

RSS
Mild reduction in food intake slows development of autosomal-dominant polycystic kidney disease

Mild reduction in food intake slows development of autosomal-dominant polycystic kidney disease

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Study: Pravastatin slows down growth of kidney cysts in children, young adults with ADPKD

Study: Pravastatin slows down growth of kidney cysts in children, young adults with ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

Component of grape, citrus fruits block formation of kidney cysts

Component of grape, citrus fruits block formation of kidney cysts

Research uncovers defective process in patients with autosomal dominant polycystic kidney disease

Research uncovers defective process in patients with autosomal dominant polycystic kidney disease

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Tolvaptan improves kidney health in polycystic kidney disease

Tolvaptan improves kidney health in polycystic kidney disease

Study highlights potential treatment that reduces kidney growth

Study highlights potential treatment that reduces kidney growth

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Potential new drug to treat common inherited kidney disease

Potential new drug to treat common inherited kidney disease

RA drug reduces kidney cyst growth in ADPKD mouse model

RA drug reduces kidney cyst growth in ADPKD mouse model

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.